{"generic":"Collagenase, Clostridium histolyticum","drugs":["Collagenase, Clostridium histolyticum","Xiaflex"],"mono":{"0":{"id":"929586-s-0","title":"Generic Names","mono":"Collagenase, Clostridium histolyticum"},"1":{"id":"929586-s-1","title":"Dosing and Indications","sub":{"0":{"id":"929586-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Dupuytren's contracture, with a palpable cord:<\/b> inject 0.58 mg INTRALESIONALLY into a palpable cord; if contracture persists after 24 to 72 hours, perform a finger extension procedure to facilitate cord disruption; if contracture remains after 4 weeks, may reinject with a single dose of 0.58 mg INTRALESIONALLY followed by finger extension procedure 24 to 72 hours later; may perform up to 3 injection and finger extension procedures per cord at 4-week intervals; may perform 2 injections in same hand per visit<\/li><li><b>Peyronie's disease:<\/b> treatment cycle: inject 0.58 mg INTRALESIONALLY for 2 injections separated by 1 to 3 days and perform a penile modeling procedure 1 to 3 days after the second injection; interval between treatment cycles is approximately 6 weeks; if after the first, second, or third treatment cycle, curvature deformity is less than 15 degrees or further treatment is not clinically indicated, subsequent treatment cycles should not be administered; MAX: 4 treatment cycles<\/li><\/ul>"},"1":{"id":"929586-s-1-5","title":"Pediatric Dosing","mono":"safety and efficacy have not been established in pediatric patients "},"3":{"id":"929586-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Dupuytren's contracture, with a palpable cord<\/li><li>Peyronie's disease<\/li><\/ul>"}}},"2":{"id":"929586-s-2","title":"Black Box Warning","mono":"<b>Injection (Powder for Solution)<\/b><br\/>Corporal rupture (penile fracture) and severe penile hematoma have been reported with use. Promptly evaluate signs or symptoms that reflect serious penile injury, as surgical intervention may be required. Collagenase clostridium histolyticum is only available through a restricted program called the Xiaflex REMS program.<br\/>"},"3":{"id":"929586-s-3","title":"Contraindications\/Warnings","sub":[{"id":"929586-s-3-9","title":"Contraindications","mono":"<ul><li>hypersensitivity to collagenase clostridium histolyticum or to collagenase used in any therapeutic application<\/li><li>Peyronie plaques involving the penile urethra<\/li><\/ul>"},{"id":"929586-s-3-10","title":"Precautions","mono":"<ul><li>Black Box Warning:<\/li><li>-- corporal rupture and other penile injuries (ie, ecchymoses, hematoma, sudden penile detumescence, or a popping sound or sensation) have been reported; monitoring recommended and surgical intervention may be required<\/li><li>Hematologic:<\/li><li>-- avoid use in patients with coagulation disorders<\/li><li>-- bleeding events including ecchymosis, contusion, hematoma, and injection site hemorrhage have been reported<\/li><li>Immunologic:<\/li><li>-- hypersensitivity reactions, including anaphylaxis, have been reported<\/li><li>-- IgE-antidrug antibodies may develop<\/li><li>Musculoskeletal:<\/li><li>-- avoid injecting drug into tendons, nerves, blood vessels, and other collagen-containing structures<\/li><li>-- flexor tendon ruptures, including permanent injuries, have been reported; increased risk with injection into collagen-containing structure (ie, tendons or ligaments)<\/li><li>-- serious local reactions in the finger or hand have been reported including pulley rupture, ligament injury, complex regional pain syndrome, sensory abnormality of the hand, and skin laceration; monitoring recommended and surgical intervention may be required<\/li><li>Reproductive:<\/li><li>-- inject drug only into the Peyronie's plaque; avoid injection into urethra, nerves, blood vessels, corpora cavernosa, and other collagen-containing structures<\/li><li>-- increased risk of penile injury with injection into collagen-containing structures<\/li><li>Concomitant use:<\/li><li>-- avoid concomitant use of anticoagulants (except for low-dose aspirin)<\/li><\/ul>"},{"id":"929586-s-3-11","title":"Pregnancy Category","mono":"B (FDA)<br\/>"},{"id":"929586-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"929586-s-4","title":"Drug Interactions","sub":{"1":{"id":"929586-s-4-14","title":"Major","mono":"<ul><li>Acenocoumarol (theoretical)<\/li><li>Apixaban (theoretical)<\/li><li>Ardeparin (theoretical)<\/li><li>Argatroban (theoretical)<\/li><li>Bivalirudin (theoretical)<\/li><li>Certoparin (theoretical)<\/li><li>Dabigatran Etexilate (theoretical)<\/li><li>Dalteparin (theoretical)<\/li><li>Danaparoid (theoretical)<\/li><li>Desirudin (theoretical)<\/li><li>Enoxaparin (theoretical)<\/li><li>Fondaparinux (theoretical)<\/li><li>Heparin (theoretical)<\/li><li>Lepirudin (theoretical)<\/li><li>Nadroparin (theoretical)<\/li><li>Parnaparin (theoretical)<\/li><li>Phenindione (theoretical)<\/li><li>Phenprocoumon (theoretical)<\/li><li>Protein C (theoretical)<\/li><li>Reviparin (theoretical)<\/li><li>Rivaroxaban (theoretical)<\/li><li>Tinzaparin (theoretical)<\/li><li>Warfarin (theoretical)<\/li><\/ul>"}}},"5":{"id":"929586-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Cardiovascular:<\/b>Peripheral edema (Dupuytren contracture, 73%)<\/li><li><b>Dermatologic:<\/b>Injection site hemorrhage (Dupuytren contracture, 38%), Injection site reaction (Dupuytren contracture, 35%), Pruritus (Dupuytren contracture, 15%; Peyronie disease, 4%), Skin tenderness (Dupuytren contracture, 24%), Swelling at injection site (Dupuytren contracture, 24%)<\/li><li><b>Hematologic:<\/b>Contusion (Dupuytren contracture, up to 70%), Ecchymosis (Peyronie disease, 14.5%; Dupuytren contracture, up to 70%)<\/li><li><b>Immunologic:<\/b>Antibody development, Lymphadenopathy (Dupuytren contracture, 13%)<\/li><li><b>Musculoskeletal:<\/b>Pain in limb (Dupuytren contracture, 35%)<\/li><li><b>Reproductive:<\/b>Hematoma of penis (Peyronie disease, up to 65.5%), Pain in penis (Peyronie disease, 45.4%), Penile swelling (Peyronie disease, 55%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Musculoskeletal:<\/b>Ligament injury, Finger, Rupture of tendon, Flexor (Dupuytren contracture, 0.3%)<\/li><li><b>Neurologic:<\/b>Complex regional pain syndrome, Sensory neuropathy, Hand<\/li><li><b>Reproductive:<\/b>Hematoma of penis (Severe) (Peyronie disease, 3.7% to 6%), Rupture of corpus cavernosum of penis (Peyronie disease, 0.5% to 0.9%)<\/li><\/ul>"},"6":{"id":"929586-s-6","title":"Drug Name Info","sub":{"0":{"id":"929586-s-6-17","title":"US Trade Names","mono":"Xiaflex<br\/>"},"2":{"id":"929586-s-6-19","title":"Class","mono":"<ul><li>Proteolytic Enzyme<\/li><li>Tissue Permeability Modifier<\/li><\/ul>"},"3":{"id":"929586-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"929586-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"929586-s-7","title":"Mechanism Of Action","mono":"Clostridium histolyticum collagenase consists of 2 microbial collagenases (AUX-I and AUX-II) that synergistically hydrolyze collagen resulting in lysis of collagen deposits and may result in enzymatic disruption of the cord in patients with Dupuytren contracture and in the plaque associated with Peyronie disease.<br\/>"},"8":{"id":"929586-s-8","title":"Pharmacokinetics","sub":[{"id":"929586-s-8-23","title":"Absorption","mono":"Tmax, intralesional: 10 minutes <br\/>"}]},"9":{"id":"929586-s-9","title":"Administration","mono":"<ul><li><b>General Information<\/b><br\/><ul><li>for intralesional use only<\/li><li>remove drug and diluent vial from refrigerator; allow to stand at room temperature for 15 to 60 minutes; reconstitute with the provided diluent as directed, injecting slowly into sides of vial; swirl gently to dissolve; do not invert vial or shake; may store reconstituted solution at room temperature for 1 hour or refrigerated for 4 hours prior to administration<\/li><\/ul><\/li><li><b>Intralesional<\/b><br\/><ul><li>(Dupuytren contracture) cords affecting metacarpophalangeal joint: use 0.39 mL diluent; withdraw 0.25 mL reconstituted solution (0.58 mg)<\/li><li>(Dupuytren contracture) cords affecting proximal interphalangeal joint: use 0.31 diluent; withdraw 0.2 mL reconstituted solution (0.58 mg)<\/li><li>(Dupuytren contracture) use 27 gauge, 1\/2 inch needle; if treating the proximal interphalangeal (PIP) joint of the fifth finger, inject as far proximal to digital PIP joint crease as possible at a depth of 2 to 3 mm<\/li><li>(Dupuytren contracture) confirm needle is in cord; inject approximately one-third of the dose; inject another one-third 2 to 3 mm distal to the first injection; inject final one-third dose 2 to 3 mm proximal to initial injection<\/li><li>(Dupuytren contracture) if 2 injections will be administered, use a separate syringe and vial for each injection; for 2 injections in 1 hand, start at lateral aspect and work toward medial aspect; for 2 injections in 1 cord, begin with most proximally affected finger joint and work toward most distally affected joint<\/li><li>(Peyronie disease) use 0.39 mL diluent; withdraw 0.25 mL reconstituted solution (0.58 mg)<\/li><li>(Peyronie disease) use 27 gauge, 1\/2 inch needle; injection must be performed by healthcare providers who have completed required training<\/li><li>(Peyronie disease) for second injection of treatment cycle, administer approximately 2 to 3 mm apart from first injection<\/li><li>discard unused reconstituted solution and diluent; do not store, pool or use any vials containing unused reconstituted solution or diluent<\/li><\/ul><\/li><\/ul>"},"10":{"id":"929586-s-10","title":"Monitoring","mono":"<ul><li>Dupuytren Contracture: reduction in contracture of the joint to within 0 to 5 degrees of normal, 30 days after the last injection is indicative of efficacy<\/li><li>Peyronie Disease: improvement in curvature deformity is indicative of efficacy<\/li><li>corporal rupture or severe penile hematoma in patients with signs or symptoms of serious penile injury<\/li><\/ul>"},"11":{"id":"929586-s-11","title":"How Supplied","mono":"<b>Xiaflex<\/b><br\/>Injection Powder for Solution: 0.9 MG<br\/>"},"13":{"id":"929586-s-13","title":"Clinical Teaching","mono":"<ul><li>Inform patient to avoid sexual activity for at least 2 weeks after penile injection.<\/li><li>Side effects may include tenderness, pain, warmth, pruritus, and erythema at injection site and in surrounding tissue.<\/li><li>Instruct patient to report severe pain, swelling, or bruising of the penis, difficulty urinating, blood in the urine, or inability to maintain an erection. Symptoms may be accompanied by popping or cracking.<\/li><li>Advise patient to contact doctor with symptoms of tendon rupture or serious ligament damage (inability to fully bend finger) after swelling disappears.<\/li><li>Inform patient to contact doctor with symptoms of an infection or sensory changes in the treated finger.<\/li><\/ul>"}}}